Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INXN 3001

Next Previous
Drug Profile

INXN 3001

Alternative Names: DC-IL-12; DC-RTS-IL12; IL-12 DNA; INcell-1001; ZIN-CTI-001

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intrexon Corporation
  • Developer Intrexon Corporation; ZIOPHARM Oncology
  • Class Cell therapies; Gene therapies
  • Mechanism of Action Gene transference; Interleukin-12 expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Malignant melanoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Malignant-melanoma(Late-stage disease) in USA (Intratumoural, Injection)
  • 22 Oct 2013 Preclinical in vitro data in Cancer presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2013)
  • 21 Oct 2013 Pharmacodynamics data from a preclinical trial in Cancer presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2013)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top